Intensive Care Unit, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD, 4102, Australia.
Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
Intensive Care Med. 2023 Sep;49(9):1079-1089. doi: 10.1007/s00134-023-07138-0. Epub 2023 Jul 11.
The Acute Disease Quality Initiative (ADQI) Workgroup recently released a consensus definition of sepsis-associated acute kidney injury (SA-AKI), combining Sepsis-3 and Kidney Disease Improving Global Outcomes (KDIGO) AKI criteria. This study aims to describe the epidemiology of SA-AKI.
This is a retrospective cohort study carried out in 12 intensive care units (ICUs) from 2015 to 2021. We studied the incidence, patient characteristics, timing, trajectory, treatment, and associated outcomes of SA-AKI based on the ADQI definition.
Out of 84,528 admissions, 13,451 met the SA-AKI criteria with its incidence peaking at 18% in 2021. SA-AKI patients were typically admitted from home via the emergency department (ED) with a median time to SA-AKI diagnosis of 1 day (interquartile range (IQR) 1-1) from ICU admission. At diagnosis, most SA-AKI patients (54%) had a stage 1 AKI, mostly due to the low urinary output (UO) criterion only (65%). Compared to diagnosis by creatinine alone, or by both UO and creatinine criteria, patients diagnosed by UO alone had lower renal replacement therapy (RRT) requirements (2.8% vs 18% vs 50%; p < 0.001), which was consistent across all stages of AKI. SA-AKI hospital mortality was 18% and SA-AKI was independently associated with increased mortality. In SA-AKI, diagnosis by low UO only, compared to creatinine alone or to both UO and creatinine criteria, carried an odds ratio of 0.34 (95% confidence interval (CI) 0.32-0.36) for mortality.
SA-AKI occurs in 1 in 6 ICU patients, is diagnosed on day 1 and carries significant morbidity and mortality risk with patients mostly admitted from home via the ED. However, most SA-AKI is stage 1 and mostly due to low UO, which carries much lower risk than diagnosis by other criteria.
急性病质量倡议(ADQI)工作组最近发布了脓毒症相关急性肾损伤(SA-AKI)的共识定义,结合了 Sepsis-3 和肾脏疾病改善全球结果(KDIGO)AKI 标准。本研究旨在描述 SA-AKI 的流行病学。
这是一项回顾性队列研究,于 2015 年至 2021 年在 12 个重症监护病房(ICU)进行。我们根据 ADQI 定义研究了 SA-AKI 的发生率、患者特征、时机、轨迹、治疗和相关结局。
在 84528 例住院患者中,有 13451 例符合 SA-AKI 标准,其发病率在 2021 年达到 18%的峰值。SA-AKI 患者通常从家中通过急诊部(ED)入院,从 ICU 入院到 SA-AKI 诊断的中位时间为 1 天(四分位距(IQR)1-1)。在诊断时,大多数 SA-AKI 患者(54%)患有 1 期 AKI,主要是由于仅存在低尿输出(UO)标准(65%)。与仅肌酐诊断、UO 和肌酐标准联合诊断相比,仅 UO 诊断的患者需要的肾脏替代治疗(RRT)要求较低(2.8%比 18%比 50%;p<0.001),在所有 AKI 阶段均如此。SA-AKI 院内死亡率为 18%,SA-AKI 与死亡率增加独立相关。在 SA-AKI 中,仅低 UO 诊断,与肌酐单独诊断或 UO 和肌酐标准联合诊断相比,死亡的优势比为 0.34(95%置信区间(CI)0.32-0.36)。
SA-AKI 发生在每 6 例 ICU 患者中 1 例,在第 1 天诊断,并伴有显著的发病率和死亡率风险,患者主要从家中通过 ED 入院。然而,大多数 SA-AKI 是 1 期,主要是由于低 UO,与其他标准诊断相比风险要低得多。